Skye Bioscience Inc (SKYE)

$0.66 -0.05 (-6.61%)
Market Cap 22.04M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 307,400
Avg Vol 691,030
Day's Range N/A - N/A
Shares Out 33.38M
Stochastic %K 22%
Beta 2.86
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
TerzoMillennio
TerzoMillennio Mar. 12 at 12:27 AM
$SKYE good job Aric.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 11 at 5:43 PM
$SKYE Heck of a bounce on the way back up 👆 nice
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 11 at 12:48 PM
$SKYE (-18.8% pre) Skye Bioscience GAAP EPS of -$0.36 misses by $0.06 https://ooc.bz/l/96290
0 · Reply
YazzJr
YazzJr Mar. 11 at 12:26 PM
$SKYE Yikes. Reverse split and most likely dilution after the split pretty much a guarantee now. That is if they can get anyone to buy the diluted shares. Bankruptcy becoming a real possibility for SKYE by year end. Sounded like the 300mg data is probably worthless as well.
1 · Reply
Polsky
Polsky Mar. 11 at 11:33 AM
$SKYE hahahahaha darn great results :D I can't believe some of you are stil pumping this. What will they cure next? A nose pimple? :D
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 10 at 11:32 PM
$SKYE I tried to short it.. Couldn't get it... Missed out on good money... We make money both ways in the Pitt🏟️🏟️
0 · Reply
Fellforit
Fellforit Mar. 10 at 10:10 PM
$SKYE is it buy, buy, buy or bye, bye, bye?? Come on pumpers, its on sale!! Skyerocketing after news....
0 · Reply
Fellforit
Fellforit Mar. 10 at 10:05 PM
$SKYE to the moon!!!! Same shit just different years and different names!!! Hahahahahahahaha..LIARS.....said basically all the same things when they were solving glaucoma
0 · Reply
MissionaryTrader
MissionaryTrader Mar. 10 at 9:39 PM
$SKYE was it just me, or was anyone able to decipher what Punit’s response was to the Analyst’s question about when the 300mg trial data release will happen? It sounded like he said they don’t expect that data to be meaningful to their path forward.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 9:19 PM
$SKYE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.36 down -50.00% YoY • Skye Bioscience expects its current capital to fund projected operations and key clinical milestones through Q4 2026, excluding anticipated clinical and drug manufacturing costs for a proposed Phase 2b study.
0 · Reply
Latest News on SKYE
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 9:00 PM EDT - 4 days ago

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 10, 2026, 4:01 PM EDT - 4 days ago

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Mar 5, 2026, 7:00 AM EST - 10 days ago

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Feb 2, 2026, 1:26 PM EST - 5 weeks ago

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Feb 2, 2026, 7:00 AM EST - 5 weeks ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 29, 2026, 7:00 AM EST - 6 weeks ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Skye Bioscience to Present Poster at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 7 weeks ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 16, 2026, 10:31 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 14, 2026, 10:31 AM EST - 2 months ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 12, 2026, 6:11 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Skye Provides 2026 Corporate Outlook

Jan 12, 2026, 7:00 AM EST - 2 months ago

Skye Provides 2026 Corporate Outlook

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 9, 2026, 9:45 AM EST - 2 months ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 2 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 19, 2025, 2:56 PM EST - 3 months ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 8, 2025, 7:11 AM EST - 3 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 24, 2025, 7:00 AM EST - 3 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 4 months ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 4 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 4 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 4 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 5 months ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 5 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 5 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 5 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 5 months ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 6 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 6 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 6 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 6 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

TerzoMillennio
TerzoMillennio Mar. 12 at 12:27 AM
$SKYE good job Aric.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 11 at 5:43 PM
$SKYE Heck of a bounce on the way back up 👆 nice
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 11 at 12:48 PM
$SKYE (-18.8% pre) Skye Bioscience GAAP EPS of -$0.36 misses by $0.06 https://ooc.bz/l/96290
0 · Reply
YazzJr
YazzJr Mar. 11 at 12:26 PM
$SKYE Yikes. Reverse split and most likely dilution after the split pretty much a guarantee now. That is if they can get anyone to buy the diluted shares. Bankruptcy becoming a real possibility for SKYE by year end. Sounded like the 300mg data is probably worthless as well.
1 · Reply
Polsky
Polsky Mar. 11 at 11:33 AM
$SKYE hahahahaha darn great results :D I can't believe some of you are stil pumping this. What will they cure next? A nose pimple? :D
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 10 at 11:32 PM
$SKYE I tried to short it.. Couldn't get it... Missed out on good money... We make money both ways in the Pitt🏟️🏟️
0 · Reply
Fellforit
Fellforit Mar. 10 at 10:10 PM
$SKYE is it buy, buy, buy or bye, bye, bye?? Come on pumpers, its on sale!! Skyerocketing after news....
0 · Reply
Fellforit
Fellforit Mar. 10 at 10:05 PM
$SKYE to the moon!!!! Same shit just different years and different names!!! Hahahahahahahaha..LIARS.....said basically all the same things when they were solving glaucoma
0 · Reply
MissionaryTrader
MissionaryTrader Mar. 10 at 9:39 PM
$SKYE was it just me, or was anyone able to decipher what Punit’s response was to the Analyst’s question about when the 300mg trial data release will happen? It sounded like he said they don’t expect that data to be meaningful to their path forward.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 10 at 9:19 PM
$SKYE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.36 down -50.00% YoY • Skye Bioscience expects its current capital to fund projected operations and key clinical milestones through Q4 2026, excluding anticipated clinical and drug manufacturing costs for a proposed Phase 2b study.
0 · Reply
Jangalang
Jangalang Mar. 10 at 9:02 PM
$SKYE … I have been holding this stock so long that I have watched the ticker symbol change over five times and have been handed multiple reverse splits. Run far away from this scam company.
0 · Reply
Jangalang
Jangalang Mar. 10 at 9:01 PM
$SKYE … Tax loss end of 2026. This company has been dead. 😵
0 · Reply
quadacesAAAA
quadacesAAAA Mar. 10 at 8:57 PM
$SKYE I lost money :(
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Mar. 10 at 8:12 PM
$SKYE Heck of a loss... Don't like it
0 · Reply
SkyeBioscience
SkyeBioscience Mar. 10 at 8:04 PM
Today, $SKYE reported its financial results for the fourth quarter and full year ended December 31, 2025 while also sharing a business update highlighting recent achievements and important milestones ahead. Read the release: https://ir.skyebioscience.com/news-releases/detail/255/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update #Biotech #Obesity #ClinicalDevelopment
0 · Reply
StockNews_Live
StockNews_Live Mar. 10 at 8:03 PM
$SKYE 🎯 STOCK NEWS ALERT 💵 Price: $0.80 (+10.35%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Skye Bioscience initiated the CBeyond Expansion Study to assess higher-exposure safety and pharmacokinetics of nimacimab administered intravenously at doses higher than the subcutaneous regimen used… 📎 https://stocknews.live/news/SKYE/skye-bioscience-reports-fourth-98559.html
0 · Reply
islandpunk
islandpunk Mar. 10 at 8:03 PM
$SKYE https://www.stocktitan.net/news/SKYE/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-a4g0tvf2s5bp.html
0 · Reply
24DV4NC3D
24DV4NC3D Mar. 10 at 7:51 PM
$SKYE ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - VOLUME #2 >>>>> #LISTEN! <<<<< PIVOT… .82 🎯Resistance 1 (R1) … .96 🎯Resistance 2 (R2) … 1.16 >> CONTINUATION LIKELY! << >>>>>>> LISTEN! <<<<<<<
0 · Reply
SkyeBioscience
SkyeBioscience Mar. 10 at 6:31 PM
Reminder: Join us today at 4:30 p.m. ET / 1:30 p.m. PT for $SKYE Bioscience’s webcast to discuss our fourth quarter and full year 2025 financial results and business update. The webcast will be available through our Investor Relations website: https://ir.skyebioscience.com/company-information/ir-calendar-webcasts #Biotech #Obesity #ClinicalDevelopment
0 · Reply
jackedmund99
jackedmund99 Mar. 10 at 6:27 PM
$SKYE runs all the way to 85 cents then they smack it -are they shaking it to find a loose hands or is it being manipulated again? I think it’s being manipulated if the technologies is worth half of what they talk about Stock could be $100 million company instead of 25 right now it’s bullshit technologies worth something if it proves itself and it has been somebody’s gonna pick the company up somebody’s gonna be buying this thing even if they bought it for $50 million and gained a lot of experience in value here and a stock with double this thing is on sale.
0 · Reply
topstockalerts
topstockalerts Mar. 10 at 5:04 PM
$SKYE biotech traders watching as cannabinoid therapy development progresses. These development timelines tend to bring speculative positioning.
0 · Reply
YazzJr
YazzJr Mar. 10 at 4:47 PM
$SKYE What is with the crazy volume? Even for an ER day, 15M at mid day is a crazy amount.
0 · Reply